Article Figures & Data

Figures

  • Figure 1.

    Study Design

    Data presented in No. (%).

    DB, double-blind.

    Adapted by permission from Macmillan Publishers Ltd: Nerophsychopharmacology. Koblan KS et al. Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Advance online publication 3 June 2015; doi: 10.1038/npp.2015.124. Copyright (2015).

  • Figure 2.

    Primary Outcome

    The primary efficacy measure of ADHD RS-IV (with adult prompts) total score was reduced by dasotraline 4 mg (adjusted P = .076) and 8 mg (adjusted P = .019) at 4 wk compared with placebo.

    ADHD RS-IV, Attention Deficit Hyperactivity Disorder Rating Scale version IV; LS, least squares.

    aBaseline mean, 36.8.

    bBaseline mean, 36.6.

    cBaseline mean, 36.7.

    *P < .05.

    Adapted by permission from Macmillan Publishers Ltd: Nerophsychopharmacology. Koblan KS et al. Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Advance online publication 3 June 2015; doi: 10.1038/npp.2015.124. Copyright (2015).